Hormone receptor status-Positive (ER and/or PR) Page 2 Posts on Medivizor
Navigation Menu

Hormone receptor status-Positive (ER and/or PR) Posts on Medivizor

Using palbociclib alone or with other therapies in advanced ER+ breast cancer

Posted by on Jul 3, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...

Read More

Endocrine therapy used with targeted therapy is associated with similar quality of life in comparison to endocrine therapy used alone.

Posted by on Feb 12, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone.  Some...

Read More

The optimal duration of hormone therapy for post menopausal patients with early breast cancer

Posted by on Jan 15, 2018 in Breast cancer | 0 comments

In a nutshell This study aimed to compare the benefits of taking letrozole for 2.5 years versus 5 years in post-menopausal patients with early stage breast cancer. This study found no benefit of five years extended therapy with letrozole compared to 2.5 years, after an initial five years of hormone therapy.  Some background Breast...

Read More

Endocrine therapy and targeted therapy are safe for patients over 65 with HR+/HER2- advanced breast cancer

Posted by on Dec 30, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65.  Some background There are several treatment...

Read More

Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer

Posted by on Dec 23, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to determine the effectiveness and safety of ribociclib (Kisqali) combined with a non-steroidal aromatase inhibitor in elderly patients with hormone receptor positive and HER-2 negative breast cancer. This study concluded that ribociclib improved progression free survival and was relatively safe to use...

Read More

Fulvestrant: an option for estrogen-receptor positive breast cancer that has spread

Posted by on Aug 5, 2017 in Breast cancer | 0 comments

In a nutshell This study aimed to compare fulvestrant (Faslodex) to other standard endocrine agents in patients with advanced hormone sensitive breast cancer. This study concluded that fulvestrant was as effective as the available standard endocrine agents.  Some background Advanced hormone sensitive breast cancer (BC) is cancer that has...

Read More

Comparing the effects of combined PI3K inhibitor/endocrine therapy versus endocrine therapy alone in ER-positive breast cancer

Posted by on Apr 3, 2017 in Breast cancer | 0 comments

In a nutshell This study investigated whether the addition of the PI3K inhibitor pictilisib (Stemolecule GDC-0941) can increase the anti-tumor effects of anastrozole (Arimidex) in patients with estrogen receptor-positive (ER-positive) primary breast cancer (BC). Combined treatment with pictilisib (PIC)...

Read More

Extended adjuvant therapy in hormone-receptor-positive early breast cancer

Posted by on Jan 21, 2017 in Breast cancer | 0 comments

In a nutshell This review examined the benefits of extending hormone therapy from 5 to 10 years in patients with hormone receptor positive breast cancer. The study concluded that treatment recommendations should take factors such as previous treatments and potential side effects into account. Some background Hormone-receptor (HR)-positive breast...

Read More

How likely are women with hormone receptor positive breast cancer to benefit from additional exemestane or tamoxifen?

Posted by on Jul 25, 2016 in Breast cancer | 0 comments

In a nutshell This study looked at the benefit of additional hormone therapy in premenopausal women with hormone receptor-positive HER2 negative (HR+ HER2-) early breast cancer. They found that patients at higher risk of cancer returning showed greatest benefit from exemestane (Aromasin) plus ovarian function suppression (OFS). Some background HR+...

Read More